NovoCure Limited (NVCR) Earns Daily Media Impact Rating of 0.15
Press coverage about NovoCure Limited (NASDAQ:NVCR) has been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. NovoCure Limited earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave media stories about the medical equipment provider an impact score of 46.1460400149645 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:
- Novocure Ltd. – Value Analysis (NASDAQ:NVCR) : October 3, 2017 (finance.yahoo.com)
- Zacks: Analysts Anticipate NovoCure Limited (NVCR) Will Post Quarterly Sales of $43.26 Million (americanbankingnews.com)
- NovoCure Limited (NVCR) Receives Consensus Rating of “Buy” from Analysts (americanbankingnews.com)
- Healthcare Stock on Buy Line: NovoCure Limited (NVCR) – Street Observer (press release) (streetobserver.com)
- Novocure to Report Third Quarter 2017 Financial Results (finance.yahoo.com)
Shares of NovoCure Limited (NVCR) traded down 4.625% during midday trading on Thursday, hitting $19.075. 2,537,596 shares of the stock traded hands. NovoCure Limited has a 12-month low of $5.95 and a 12-month high of $22.30. The company’s 50 day moving average price is $20.27 and its 200-day moving average price is $15.72. The stock’s market cap is $1.70 billion.
NovoCure Limited (NASDAQ:NVCR) last announced its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.01). The firm had revenue of $38.38 million for the quarter, compared to analyst estimates of $42.20 million. NovoCure Limited had a negative net margin of 75.91% and a negative return on equity of 69.48%. On average, equities research analysts expect that NovoCure Limited will post ($0.77) EPS for the current year.
Several equities analysts have commented on the stock. BidaskClub lowered shares of NovoCure Limited from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 19th. Deutsche Bank AG reiterated a “hold” rating and set a $19.00 price objective (up previously from $18.00) on shares of NovoCure Limited in a research report on Monday, July 17th. Mizuho assumed coverage on shares of NovoCure Limited in a research report on Wednesday, September 6th. They set a “buy” rating and a $25.00 price objective for the company. Finally, Zacks Investment Research lowered shares of NovoCure Limited from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $20.14.
In other news, CEO Asaf Danziger sold 274,359 shares of the business’s stock in a transaction dated Monday, July 10th. The shares were sold at an average price of $18.07, for a total transaction of $4,957,667.13. Following the transaction, the chief executive officer now owns 668,865 shares of the company’s stock, valued at approximately $12,086,390.55. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In the last three months, insiders have sold 355,414 shares of company stock worth $6,726,515. Corporate insiders own 16.70% of the company’s stock.
About NovoCure Limited
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.
Receive News & Stock Ratings for NovoCure Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure Limited and related stocks with our FREE daily email newsletter.